Unnamed: 0,title,date,stock,sentiment
969397.0,"The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",2020-06-05 07:34:00-04:00,OXFD,positive
969398.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,OXFD,positive
969399.0,70 Biggest Movers From Yesterday,2020-05-06 05:26:00-04:00,OXFD,neutral
969400.0,51 Stocks Moving In Tuesday's Mid-Day Session,2020-05-05 12:22:00-04:00,OXFD,neutral
969401.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,OXFD,positive
969402.0,Recap: Oxford Immunotec Global Q1 Earnings,2020-05-05 07:40:00-04:00,OXFD,neutral
969403.0,"Oxford Immunotec Global Q1 EPS $(0.230) Misses $(0.150) Estimate, Sales $13.900M Beat $13.450M Estimate",2020-05-05 07:23:00-04:00,OXFD,negative
969404.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,OXFD,neutral
969405.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,OXFD,neutral
969406.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,OXFD,neutral
969407.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,OXFD,negative
969408.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,OXFD,negative
969409.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,OXFD,negative
969410.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,OXFD,negative
969411.0,Oxford Immunotec Global Q4 Sales $18.1M Beat $17.06M Estimate,2020-03-02 07:04:00-05:00,OXFD,neutral
969412.0,Oxford Immunotec Highlights 2 Publications In 'Clinical Infectious Diseases' On Performance Of T-SPOT.CMV,2020-02-20 09:16:00-05:00,OXFD,neutral
969413.0,17 Diagnostics & Research Stocks Moving In Tuesday's Session,2020-01-21 14:42:00-05:00,OXFD,neutral
969414.0,"Oxford Immunotec Sees Q4 Sales $16.4M-$17.4M vs $17.37M Est., Sees FY19 Sales $72M-$73M vs $71.99M Est.",2019-11-05 07:10:00-05:00,OXFD,neutral
969415.0,"Oxford Immunotec Global Q3 EPS $0.03 Beats $(0.03) Estimate, Sales $21.2M Beat $20.31M Estimate",2019-11-05 07:09:00-05:00,OXFD,neutral
969416.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,OXFD,negative
969417.0,46 Biggest Movers From Yesterday,2019-09-24 04:02:00-04:00,OXFD,neutral
969418.0,Oxford Immunotec Global shares are trading higher following reports indicating the company is exploring strategic alternatives.,2019-09-23 14:48:00-04:00,OXFD,positive
969419.0,Oxford Immunotec Exploring Strategic Alternatives,2019-09-23 14:47:00-04:00,OXFD,neutral
969420.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,OXFD,neutral
969421.0,"Oxford Immunotec Sees Q3 Sales $20M-$21M vs $19.03M Est., Sales $71M-$73M vs $70.57M Est.",2019-08-06 07:38:00-04:00,OXFD,neutral
969422.0,"Oxford Immunotec Global Q2 EPS $0.02 Beats $(0.04) Estimate, Sales $19.6M Beat $19.39M Estimate",2019-08-06 07:37:00-04:00,OXFD,neutral
969423.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,OXFD,neutral
969424.0,"Oxford Immunotec Global Q1 EPS $(0.06) Beats $(0.16) Estimate, Sales $14.79M Beat $13.82M Estimate",2019-05-09 07:43:00-04:00,OXFD,neutral
969425.0,Oxford Immunotec Announces Initiative To Expand Its T-SPOT.TB Test In NOTE: Russia T-SPOT Received Russian Approval In 2013,2019-03-28 07:47:00-04:00,OXFD,positive
969426.0,Oxford Immunotec Appoints Matthew McLaughlin CFO,2019-03-21 16:03:00-04:00,OXFD,neutral
969427.0,56 Biggest Movers From Yesterday,2019-03-13 06:04:00-04:00,OXFD,neutral
969428.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-12 14:06:00-04:00,OXFD,neutral
969429.0,Oxford Immunotec shares are trading higher after the company reported better-than-expected Q4 sales and provided FY19 sales guidance above analyst estimates.,2019-03-12 09:59:00-04:00,OXFD,positive
969430.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,OXFD,positive
969431.0,Oxford Immunotec Sees FY19 Sales $69M-$72M vs $69.85M Est.,2019-03-11 16:12:00-04:00,OXFD,neutral
969432.0,"Oxford Immunotec Global Q4 EPS $5.23 Does Not Compare To $(0.19) Estimate, Sales $15.37M Beat $15.1M Estimate",2019-03-11 16:12:00-04:00,OXFD,neutral
969433.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,OXFD,neutral
969434.0,Oxford Immunotec Board Approves $100M Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018 Ahead of J.P. Morgan Healthcare Conference,2019-01-06 19:52:00-05:00,OXFD,positive
969435.0,Oxford Immunotec Reports Regulatory Acceptance Of T-Cell Select In China,2018-12-07 09:01:00-05:00,OXFD,positive
969436.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,OXFD,neutral
969437.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,OXFD,positive
969438.0,51 Biggest Movers From Yesterday,2018-09-26 05:17:00-04:00,OXFD,neutral
969439.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-09-25 13:06:00-04:00,OXFD,neutral
969440.0,Quest Diagnostics To Acquire U.S. Laboratory Services Business Of Oxford Immunotec,2018-09-25 09:04:00-04:00,OXFD,neutral
969441.0,"Oxford Immunotec Global PLC Shares Up 10% After Co. Announces Quarterly Financial Results; EPS $(0.25), Inline, Sales $29.318M Beat $28.55M Estimate; Co. Also Announced Launch Of T-Cell Select In Europe",2018-07-31 11:58:00-04:00,OXFD,positive
969442.0,Oxford Immunotec Global Sees FY18 Sales $112M-$115M vs $112.85M Est.,2018-07-31 07:27:00-04:00,OXFD,neutral
969443.0,"Oxford Immunotec Global Q2 EPS $(0.25), Inline, Sales $29.318M Beat $28.55M Estimate",2018-07-31 07:25:00-04:00,OXFD,neutral
969444.0,Oxford Immunotec Sees FY18 Sales $112-$115M vs $112.3M Est.,2018-05-01 07:06:00-04:00,OXFD,neutral
969445.0,"Oxford Immunotec Q1 EPS $(0.40) Beats $(0.45) Est., Sales $21.37M Beats $20.9M Est.",2018-05-01 07:06:00-04:00,OXFD,neutral
969446.0,"Oxford Immunotec Reports Q4 EPS $0.33 vs $(0.22) In Prior Year Period, Sales $25.02M vs $23.70M In Prior Year Period",2018-02-27 07:06:00-05:00,OXFD,neutral
969447.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,OXFD,neutral
969448.0,38 Stocks Moving In Monday's Mid-Day Session,2018-01-08 12:20:00-05:00,OXFD,neutral
969449.0,Mid-Morning Market Update: Markets Down; Kohl's Raises Earnings Forecast,2018-01-08 10:13:00-05:00,OXFD,neutral
969450.0,"Oxford Immunotec Cuts Q4 Sales Guidance From $25.4M-$26.4M To $24.9M-$25.4M vs $26.1M Est.; Narrows, Cuts FY17 Sales Guidance From $103.5M-$104.5M To $103M-$103.5M vs $104.1M Est.",2018-01-08 08:39:00-05:00,OXFD,negative
969451.0,"Oxford Immunotec, QIAGEN Report Settlement Of Patent Infringement Suit; All Claims Have Been Resolved; Oxford Has Granted QIAGEN Royalty-Free, Non-Exclusive License To All Current/Future Customers In Exchange For Lump-Sum Payment Of $27.5M",2017-12-15 16:06:00-05:00,OXFD,negative
969452.0,46 Biggest Movers From Yesterday,2017-11-01 05:27:00-04:00,OXFD,neutral
969453.0,Oxford Immunotec Narrows FY17 Sales Outlook From $103M-$106M To $103.5M-$104.5M,2017-10-31 07:16:00-04:00,OXFD,neutral
969454.0,Oxford Immunotec Sees Q4 Sales $25.4M-$26.4M vs $27M Est.,2017-10-31 07:16:00-04:00,OXFD,neutral
969455.0,"Oxford Immunotec Reports Q3 EPS $(0.70) vs $(0.18) In Same Qtr. Last Year, Sales $30.429M vs $30.05M Est.",2017-10-31 07:16:00-04:00,OXFD,neutral
969456.0,"Benzinga's Top Upgrades, Downgrades For September 28, 2017",2017-09-28 09:08:00-04:00,OXFD,positive
969457.0,"BTIG Research Initiates Coverage On Oxford Immunotec Global PLC - Ordinary Shares with Buy Rating, Announces $21.00 Price Target",2017-09-28 07:37:00-04:00,OXFD,positive
969458.0,UPDATE: Oxford Immunotec Says 'We continue to look forward to the further defense of our patents at the upcoming trial in January',2017-09-27 09:26:00-04:00,OXFD,positive
969459.0,Oxford Immunotec Global Offers Update In Patent Infringement Case: 'we are disappointed that the court did not grant a preliminary injunction prohibiting the sale of Qiagen's QFT-Plus product in the U.S. before trial',2017-09-27 09:26:00-04:00,OXFD,negative
969460.0,Oxford Immunotec Names Stefan Linn COO,2017-08-30 09:01:00-04:00,OXFD,neutral
969461.0,Oxford Immunotec Global Prices 2.5M Share Offering For Gross Proceeds $40.125M,2017-08-15 09:01:00-04:00,OXFD,negative
969462.0,Oxford Immunotec Announces Offering 2.5M Shares Common Stock,2017-08-14 16:22:00-04:00,OXFD,positive
969463.0,"Oxford Immunotec Sees Q3 Sales $29.5-$30.5M vs $30.3M Est., FY17 Sales $103-$106M vs $104.1M Est.",2017-08-01 07:03:00-04:00,OXFD,neutral
969464.0,"Oxford Immunotec Reports Q2 EPS $(0.74) Does Not Compare To $(0.32) Est., Sales $26.12M vs $25.05M Est.",2017-08-01 07:03:00-04:00,OXFD,neutral
969465.0,Oxford Immunotec Global Reports Favorable Claim Construction Ruling Related To Patent Infringement Case,2017-06-15 16:06:00-04:00,OXFD,neutral
969466.0,"Oxford Immunotec Reports Q1 EPS $(0.36) vs $(0.35) Est., Sales $21.5M vs $21.2M Est.",2017-05-02 07:45:00-04:00,OXFD,neutral
969467.0,"Oxford Immunotec Sees Q1 Sales $20.8-$21.3M vs. $22.6M Est., FY17 Sales $102-$105M vs. $105M Est.",2017-02-28 16:22:00-05:00,OXFD,neutral
969468.0,"Oxford Immunotec Reports Q4 EPS $(0.22) vs. $(0.39) Est., Sales $23.7M vs. $22.9M Est.",2017-02-28 16:21:00-05:00,OXFD,neutral
969469.0,"JP Morgan Healtchare Conf. Continues Today; Presenters Include Novocure, Zoetis, Oxford Immunotec, Enanta, Irhythm Tech, Walgreen's, & Mylan",2017-01-11 08:34:00-05:00,OXFD,positive
969470.0,Immunotec Raises FY16 Rev. $82.5-$84.5M To $85-$85.8M,2016-11-01 07:08:00-04:00,OXFD,neutral
969471.0,"Oxford Immunotec Reports Q3 EPS $(0.18) vs. Est. $(0.33), Rev. $26.1M vs. Est. $24.7M",2016-11-01 07:07:00-04:00,OXFD,neutral
969472.0,"Oxford Immunotec Acquires Immunetics, Inc.  For $6M Cash And $6M Cash Payable On Certain Rev. Thresholds and Milestones",2016-10-12 16:06:00-04:00,OXFD,positive
969473.0,Oxford Immunotec Reports Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation,2016-10-03 16:02:00-04:00,OXFD,negative
969474.0,Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation,2016-09-01 07:03:00-04:00,OXFD,negative
969475.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-02 12:42:00-04:00,OXFD,neutral
969476.0,"Top Performing Industries For August 2, 2016",2016-08-02 10:47:00-04:00,OXFD,positive
969477.0,"Oxford Immunotec Reports Q2 EPS $(0.29) vs. Est. $(0.33), Rev. $19.15M vs. Est. $18.1M",2016-08-02 07:04:00-04:00,OXFD,neutral
969478.0,Oxford Immunotec Raises FY16 Guidance From $74M-$77M To $79.5M-$82.5M,2016-06-23 16:06:00-04:00,OXFD,neutral
969479.0,Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen For $22.2M All Cash,2016-06-23 16:06:00-04:00,OXFD,positive
969480.0,Oxford Immunotec Sees Q2 Sales $17.4M-$18.2M vs $17.9M Est.; Sees FY16 Sales $74M-$77M vs $76.2M Est.,2016-05-03 07:13:00-04:00,OXFD,neutral
969481.0,"Oxford Immunotec Reports Q1 EPS $(0.32), Inline, Sales $17.1M vs $17M Est.",2016-05-03 07:12:00-04:00,OXFD,neutral
969482.0,Oxford Immunotec Sees Q1 Sales $16.6M-$17.3M vs $17.7M Est.; Sees FY16 Sales $74M-$77M vs $79.7M Est.,2016-03-01 07:15:00-05:00,OXFD,neutral
969483.0,"Oxford Immunotec Reports Q4 EPS $(0.29) vs $(0.28) Est., Sales $16.8M vs $16.3M Est.",2016-03-01 07:14:00-05:00,OXFD,neutral
969484.0,"Oxford Immunotec Global Reports Q2 Revs $14.3M Vs Est $14.04M, Sees Q3 Revs $16.8M-$17.6M Vs Est $17.44; Sees FY 2015 Revs $61M-$64M Vs Est $62.12M",2015-08-04 07:23:00-04:00,OXFD,neutral
969485.0,"Oxford Immunotec Reports Exclusive Licensing Agreement With IDIBELL for B Cell Measurement, Technology Featured in Study Published in Kidney International",2015-07-15 16:43:00-04:00,OXFD,positive
969486.0,Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV,2015-06-11 07:31:00-04:00,OXFD,neutral
969487.0,"Oxford Immunotec Names Stephen M Gansler As SVP, GLobal Head Of Human Resources",2015-03-17 11:53:00-04:00,OXFD,neutral
969488.0,Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT,2015-02-05 07:19:00-05:00,OXFD,positive
969489.0,Oxford Immunotec Global PLC Announces Proposed Underwritten Offering of Ordinary Shares,2015-01-28 16:35:00-05:00,OXFD,positive
969490.0,Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test,2015-01-06 07:32:00-05:00,OXFD,neutral
969491.0,Oxford Immunotec To Acquire Assets From Boulder Diagnostic For $7.9M,2014-08-05 07:15:00-04:00,OXFD,positive
969492.0,Oxford Immunotec Reports Q2 EPS of $(0.36) Which May Not Compare $(0.20) Est; Revenue of $11.79M Which May Not Compare $11.39M Est,2014-08-05 07:14:00-04:00,OXFD,neutral
969493.0,7 Stocks To Watch Ahead Of Lockup Expirations And PDUFA Dates ,2014-05-19 16:00:00-04:00,OXFD,neutral
969494.0,Financial Times Reports Large Number of US Biotech IPOs Could Indicate Bubble is Near,2014-02-09 10:35:00-05:00,OXFD,positive
969495.0,"IPO of Oxford Immunotec Opens at $14, Priced at $12/Share",2013-11-22 10:28:00-05:00,OXFD,neutral
969496.0,Oxford Immunotec Global Prices 5.36M Share IPO at $12.00/Share,2013-11-22 08:48:00-05:00,OXFD,positive
969497.0,Oxford Immunotec Prices 5.36M Shares at $12/Share in IPO,2013-11-22 08:16:00-05:00,OXFD,positive
